Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(11)
•••
Comment by pattyb77on Nov 29, 2018 4:35pm
86 Views
Post# 29041974

RE:IR response?

RE:IR response?No responses yet. But here are the questions 

Here's our list of questions I will send off to Robert tomorrow. TODAY is the last day to submit questions.
 
 Has Kalytera been presented with any buyout offers in 2018 from a group that isn't Salzman?
 
Has Kalytera had any offers to fully fund phase 3 without further dilution of stock?
 
Is APH going to invest again or can they?
 
Are there any delays investors should be aware of?
 
What are revenues looking like? 
 
Does Kalytera plan to bring anything to market in short term to help fund trials? 
 
How much cash on hand?
 
Is the FDA decision for Revive Therapeutics going to help fast track Kalytera?
 
Could you provide investors a run down of how Kalytera’s product development program works and what stage we are currently at and what stage is next?
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities